Hu J X, Jia G X, Yan Z R
General Hospital of Air Force, PLA of China, Beijing.
Zhong Xi Yi Jie He Za Zhi. 1990 Oct;10(10):596-9, 580.
Shenshao Tongguan Pian (SSTGP) is composed chiefly of saponins from the stem and leaf of Ginseng and Radix Paeoniae Alba, etc. The authors applied this remedy for the treatment of angina pectoris of CHD. From 1982-1988, the authors carried out a randomized double blind trial on altogether 565 cases of CHD divided into an experimental group to be treated with SSTGP and a control group treated with another TCM proprietory medicine, Dan Qi Pian, that had been used for many years clinically. The total effective rate of treating angina pectoris was 94.71% and ECG improvement rate 63.38% in experimental group whereas 66.99% and 23.38% respectively in the control group, the difference being very significant (P less than 0.01). Experiments with animals proved that SSTGP had more potent actions on CV system, such as dilatation of coronary arteries, promotion of coronary perfusion flow, lowering oxygen consumption of heart muscle, resisting the coronary spasm, anoxia and ischemia of heart muscle elicited by pituitrin, and prolongation of survival time of mice under anoxic state. In addition, laboratory examination also revealed SSTGP could promote the left ventricular output, lower the blood viscosity and inhibit the aggregation of blood platelets. Both acute and chronic toxicity tests showed SSTGP has no toxicity nor side effects. Therefore SSTGP is a new, safe and effective TCM proprietory remedy for CHD and angina pectoris.
参芍通冠片（SSTGP）主要由人参茎叶皂苷和白芍等组成。作者应用该制剂治疗冠心病心绞痛。1982年至1988年，作者对共565例冠心病患者进行了随机双盲试验，分为实验组用参芍通冠片治疗，对照组用另一种临床已使用多年的中药成药丹七片治疗。治疗心绞痛的总有效率实验组为94.71%，心电图改善率为63.38%；而对照组分别为66.99%和23.38%，差异非常显著（P＜0.01）。动物实验证明，参芍通冠片对心血管系统有较强作用，如扩张冠状动脉、促进冠脉灌注流量、降低心肌耗氧量、对抗垂体后叶素引起的冠脉痉挛、心肌缺氧和缺血，延长小鼠在缺氧状态下的存活时间。此外，实验室检查还显示参芍通冠片可促进左心室输出，降低血液粘度，抑制血小板聚集。急性和慢性毒性试验均表明参芍通冠片无毒副作用。因此，参芍通冠片是一种治疗冠心病和心绞痛的新型、安全有效的中药成药。
